Data Exchange Profiles for 2022 CDC Clinical Practice Guideline for Prescribing Opioids, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/cdc-opioid-cpg/ and changes regularly. See the Directory of published versions
| Page standards status: Informative |
| CodeSystem | Description |
|---|
| ValueSet | Description |
|---|---|
| Amphetamine-class drugs and metabolite urine tests | Urine tests, both quantitative and qualitative, including confirmatory, that detect Amphetamine-class drugs and metabolites |
| Amphetamine class medications | Amphetamine class medications based upon the mapping of SNOMED CT drug class to ingredient then linked to RXNorm |
| Barbiturate Medications | All Barbiturate medications |
| Barbiturate urine drug screening tests | Presumed general urine tests for barbiturates that are not specific to a particular substance. |
| Benzodiazepine medications | All benzodiazepine clinical drugs |
| Benzodiazepine urine drug screening tests | Presumed general urine tests for benzodiazepines that are not specific to a particular substance. |
| Buprenorphine Medications | All Buprenorphine medications |
| Buprenorphine urine drug screening tests | Presumed general urine tests for buprenorphine. |
| Cannabinoid class urine drug screening | Cannabinoid, including synthetic and THC, urine tests |
| CDC malignant cancer conditions | All neoplastic and malignant conditions, including pain due to neoplasm. |
| CNS depressant medications | Medications considered to have an ingredient considered to be a CNS depressant, some of which may be mild. Removed from this set are cough medications and bowl transit modifiers. |
| Cocaine urine drug screening tests | Urine tests for cocaine and cocaine metabolites |
| Conditions likely terminal for opioid prescribing | Conditions that generally are thought to have terminal prognosis |
| Extended release opioid with ambulatory misuse potential | All opioid clinical drugs except those restricted to surgical use only, and that are in an extended release dose form code |
| Fentanyl-type medications | Fentanyl and similar medications (sufentanil, alfentanil, remifentanil) |
| Fentanyl-type urine drug screening tests | Urine tests for fentanyl-type drugs and metabolites |
| General opiate urine drug screening tests | Presumed general urine tests for naturally occurring opioids (i.e. opiates) that are not specific to a particular substance based upon the inclusion of the word 'opiates' in the long name. |
| Heroin urine drug screening tests | Presumed general urine tests for heroin and metabolites. |
| Methadone medications | Medication codes representing methadone medications |
| Methadone urine drug screening tests | Urine tests to identify methadone and metabolites |
| Naloxone medications | All naloxone medications |
| Non-synthetic opioid medications | Medications derived from the opium plant that are not synthetically created . All metabolize to morphine. |
| Opioid analgesics with ambulatory misuse potential | All opioid clinical drugs except cough medications, antispasmodics, or those restricted to surgical use only as identified by those using an injectable form. |
| Opioid misuse assessment procedure | Procedure to assess the risk of opioid abuse occurring by a patient |
| Oxycodone Medications | All Oxycodone medications |
| Oxycodone urine drug screening tests | Presumed general urine tests for oxycodone. |
| Pain management procedure | Procedure for subacute or chronic pain control management |
| Pain treatment plan | A Pain medicine Plan of care note |
| PDMP data reviewed finding | Finding indicating that the Prescription Drug Monitoring Program (PDMP) data was reviewed |
| PDMP review procedure | Procedure for Prescription Drug Monitoring Program (PDMP) review |
| Phencyclidine urine drug screening tests | Urine tests for phencyclidine |
| Sickle-cell diseases | Sickle-cell disorders that cause painful crisis |